StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Aerie Pharma (AERI) Announces Rhopressa Phase 3 Met Primary Efficacy Endpoint
September 16, 2015 4:04 PM
Aerie Pharma (NASDAQ: AERI) reported the successful results of its second Phase 3 trial for Rhopressa™, a novel once-daily, triple-action ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Management Comments
Next Articles
Canaccord Genuity Raised Price target on Aerie Pharma (AERI) Following Rocket 2 Data
September 17, 2015 10:09 AM
RBC Capital Boosts PT on Aeri Pharma (AERI) to $44 Following Rhopressa Phase 3 Data
September 17, 2015 9:00 AM
Aerie Pharma (AERI) PT Raised to $40 at Cantor Fitzgerald
September 17, 2015 7:24 AM
Aerie Pharma (AERI) PT Raised to $48 at Brean Capital
September 17, 2015 6:59 AM
Aerie Pharma (AERI) PT Raised to $45 at Needham & Company
September 17, 2015 6:22 AM
Form 8-K AERIE PHARMACEUTICALS For: Sep 16
September 16, 2015 4:02 PM
Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results
September 16, 2015 4:01 PM
